Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
$1.50
-0.3%
$1.16
$0.86
$3.60
$91.16M0.11295,894 shs197,880 shs
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
$1.26
-1.2%
$1.29
$0.97
$1.94
$60.57M0.5132,591 shs294,428 shs
InterCure Ltd. stock logo
INCR
InterCure
$1.53
+0.3%
$1.52
$1.17
$2.62
$69.27M1.1818,077 shs12,468 shs
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$0.95
+0.4%
$0.96
$0.79
$4.38
$18.84M0.79147,754 shs136,246 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
0.00%+7.14%+25.00%+41.51%-47.74%
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
0.00%-7.97%-6.62%+11.40%-23.49%
InterCure Ltd. stock logo
INCR
InterCure
0.00%-2.25%0.00%+12.59%-33.91%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
0.00%+7.33%-1.51%-31.98%-65.37%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
2.7445 of 5 stars
3.54.00.00.01.31.70.6
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
2.795 of 5 stars
3.33.00.00.02.01.71.3
InterCure Ltd. stock logo
INCR
InterCure
0.4912 of 5 stars
0.03.00.00.02.00.00.6
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
1.7267 of 5 stars
3.52.00.00.00.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
3.00
Buy$6.33323.63% Upside
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
2.50
Moderate Buy$3.00139.04% Upside
InterCure Ltd. stock logo
INCR
InterCure
0.00
N/AN/AN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
3.00
Buy$5.00426.87% Upside

Current Analyst Ratings Breakdown

Latest LEXX, ABOS, INCR, and IKNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$7.00 ➝ $5.00
6/17/2025
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$4.00
(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
N/AN/AN/AN/A$3.03 per shareN/A
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
$9.16M6.61N/AN/A$2.61 per share0.48
InterCure Ltd. stock logo
INCR
InterCure
$66.28MN/AN/AN/A$2.36 per shareN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
$460K40.35N/AN/A$0.48 per share1.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$102.33M-$1.94N/AN/AN/AN/A-58.24%-46.53%8/12/2025 (Estimated)
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
-$49.23M-$0.86N/AN/AN/AN/A-30.59%-27.55%8/14/2025 (Estimated)
InterCure Ltd. stock logo
INCR
InterCure
-$18.32MN/A0.00N/AN/AN/AN/A8/28/2025 (Estimated)
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-$5.80M-$0.67N/AN/AN/A-1,849.19%-157.22%-133.69%N/A

Latest LEXX, ABOS, INCR, and IKNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
-$0.14N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$0.54N/AN/AN/AN/AN/A
7/14/2025Q3 2025
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
-$0.15-$0.21-$0.06-$0.21$0.17 million$0.17 million
5/13/2025Q1 2025
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
-$0.56-$0.48+$0.08-$0.48N/AN/A
5/8/2025Q1 2025
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
-$0.21-$0.18+$0.03-$0.18N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
N/AN/AN/AN/AN/A
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
N/AN/AN/AN/AN/A
InterCure Ltd. stock logo
INCR
InterCure
N/AN/AN/AN/AN/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
0.19
8.02
8.02
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
N/A
13.31
13.31
InterCure Ltd. stock logo
INCR
InterCure
0.34
1.73
1.18
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
N/A
3.90
3.90

Institutional Ownership

CompanyInstitutional Ownership
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
71.01%
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
75.00%
InterCure Ltd. stock logo
INCR
InterCure
8.34%
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
13.06%

Insider Ownership

CompanyInsider Ownership
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
7.10%
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
5.94%
InterCure Ltd. stock logo
INCR
InterCure
N/A
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
26.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acumen Pharmaceuticals, Inc. stock logo
ABOS
Acumen Pharmaceuticals
2060.57 million56.27 millionOptionable
Ikena Oncology, Inc. stock logo
IKNA
Ikena Oncology
7048.26 million45.39 millionNot Optionable
InterCure Ltd. stock logo
INCR
InterCure
350N/AN/AOptionable
Lexaria Bioscience Corp. stock logo
LEXX
Lexaria Bioscience
719.56 million14.40 millionNot Optionable

Recent News About These Companies

LEXX - Lexaria Bioscience Corp Dividends - Morningstar
Lexaria Attending BIO International Convention
Lexaria Attending BIO International Convention
Lexaria provides GLP-1 update following industry developments

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Acumen Pharmaceuticals stock logo

Acumen Pharmaceuticals NASDAQ:ABOS

$1.50 -0.01 (-0.33%)
As of 12:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Ikena Oncology stock logo

Ikena Oncology NASDAQ:IKNA

$1.25 -0.02 (-1.18%)
As of 12:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

InterCure stock logo

InterCure NASDAQ:INCR

$1.52 +0.01 (+0.33%)
As of 12:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

Lexaria Bioscience stock logo

Lexaria Bioscience NASDAQ:LEXX

$0.95 +0.00 (+0.37%)
As of 12:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.